350 related articles for article (PubMed ID: 32568634)
1. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA; O'Carrigan B; Penney MS; Lim JS; Brown JS; de Miguel Luken MJ; Tunariu N; Perez-Lopez R; Rodrigues DN; Riisnaes R; Figueiredo I; Carreira S; Hare B; McDermott K; Khalique S; Williamson CT; Natrajan R; Pettitt SJ; Lord CJ; Banerji U; Pollard J; Lopez J; de Bono JS
J Clin Oncol; 2020 Sep; 38(27):3195-3204. PubMed ID: 32568634
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Thomas A; Redon CE; Sciuto L; Padiernos E; Ji J; Lee MJ; Yuno A; Lee S; Zhang Y; Tran L; Yutzy W; Rajan A; Guha U; Chen H; Hassan R; Alewine CC; Szabo E; Bates SE; Kinders RJ; Steinberg SM; Doroshow JH; Aladjem MI; Trepel JB; Pommier Y
J Clin Oncol; 2018 Jun; 36(16):1594-1602. PubMed ID: 29252124
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Middleton MR; Dean E; Evans TRJ; Shapiro GI; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R
Br J Cancer; 2021 Aug; 125(4):510-519. PubMed ID: 34040175
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Terranova N; Jansen M; Falk M; Hendriks BS
Cancer Chemother Pharmacol; 2021 Feb; 87(2):185-196. PubMed ID: 33145616
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Shapiro GI; Wesolowski R; Devoe C; Lord S; Pollard J; Hendriks BS; Falk M; Diaz-Padilla I; Plummer R; Yap TA
Br J Cancer; 2021 Aug; 125(4):520-527. PubMed ID: 34040174
[TBL] [Abstract][Full Text] [Related]
6. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Gorecki L; Andrs M; Rezacova M; Korabecny J
Pharmacol Ther; 2020 Jun; 210():107518. PubMed ID: 32109490
[TBL] [Abstract][Full Text] [Related]
7. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study.
Yap TA; Krebs MG; Postel-Vinay S; El-Khouiery A; Soria JC; Lopez J; Berges A; Cheung SYA; Irurzun-Arana I; Goldwin A; Felicetti B; Jones GN; Lau A; Frewer P; Pierce AJ; Clack G; Stephens C; Smith SA; Dean E; Hollingsworth SJ
Clin Cancer Res; 2021 Oct; 27(19):5213-5224. PubMed ID: 34301752
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors.
Yap TA; Tolcher AW; Plummer R; Mukker JK; Enderlin M; Hicking C; Grombacher T; Locatelli G; Szucs Z; Gounaris I; de Bono JS
Clin Cancer Res; 2024 May; 30(10):2057-2067. PubMed ID: 38407317
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC; Bischoff HG; Hwang J; Reinhardt HC; Zander T; Wang X; Hynes S; Pitou C; Campbell R; Iversen P; Farrington DL; Bell-McGuinn K; Thomas M
Invest New Drugs; 2020 Aug; 38(4):1145-1155. PubMed ID: 31707688
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R; Charrier JD; Durrant S; Davis C; O'Donnell M; Storck P; MacCormick S; Kay D; Pinder J; Virani A; Twin H; Griffiths M; Reaper P; Littlewood P; Young S; Golec J; Pollard J
J Med Chem; 2019 Jun; 62(11):5547-5561. PubMed ID: 31074988
[TBL] [Abstract][Full Text] [Related]
13. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
14. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER; Sarker D; Bhosle J; Thillai K; Yap TA; Uttenreuther-Fischer M; Pemberton K; Jin X; Wiebe S; de Bono J; Spicer J
Cancer Chemother Pharmacol; 2018 Nov; 82(5):757-766. PubMed ID: 30088048
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Von Hoff DD; Rasco DW; Heath EI; Munster PN; Schellens JHM; Isambert N; Le Tourneau C; O'Neil B; Mathijssen RHJ; Lopez-Martin JA; Edenfield WJ; Martin M; LoRusso PM; Bray GL; DiMartino J; Nguyen A; Liu K; Laille E; Bendell JC
Clin Cancer Res; 2018 Sep; 24(17):4072-4080. PubMed ID: 29764853
[No Abstract] [Full Text] [Related]
18. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
19. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
